Department of Medical Oncology, St Bartholomew's Hospital, King George V Building, West Smithfield, London, EC1A 7BE, UK.
Barts Cancer Institute, Queen Mary University of London, London, UK.
Breast Cancer Res Treat. 2022 May;193(1):21-35. doi: 10.1007/s10549-022-06547-x. Epub 2022 Mar 2.
The use of immune checkpoint inhibitors in combination with chemotherapy for the treatment of triple-negative breast cancer is becoming more widespread as efficacy data accumulates. However, outcomes remain less than optimal and not all patients benefit from treatment. The aim of this article is to review the emerging chemoimmunotherapy strategies for triple-negative breast cancer.
Searches were undertaken on Pubmed and Clinicaltrials.gov for relevant publications and trials.
Preclinical and clinical data have provided insights into the differing immunomodulatory effects of chemotherapy agents, highlighting the immunostimulatory properties of anthracyclines. Mechanisms of resistance to immune checkpoint inhibition are discussed and the potential role of phosphatidylinositol 3-kinase (PI3K)/AKT and MAPK/ERK kinase (MEK) inhibitors in overcoming resistance. Finally, the emerging therapeutic class of antibody-drug conjugates for triple-negative breast cancer in combination with immune checkpoint inhibitors is reviewed.
The type and sequence of chemotherapy agents play an important role in optimising the response to immune checkpoint inhibitors. Antibody-drug conjugates in combination with immune checkpoint inhibitors are a promising area of development.
随着疗效数据的积累，免疫检查点抑制剂与化疗联合用于治疗三阴性乳腺癌的应用越来越广泛。然而，治疗效果仍不尽如人意，并非所有患者都从中获益。本文旨在综述三阴性乳腺癌的新兴化疗免疫治疗策略。
在 Pubmed 和 Clinicaltrials.gov 上进行了相关出版物和试验的检索。
临床前和临床数据深入了解了化疗药物的不同免疫调节作用，强调了蒽环类药物的免疫刺激特性。讨论了对免疫检查点抑制的耐药机制，以及磷脂酰肌醇 3-激酶（PI3K）/AKT 和丝裂原活化蛋白激酶/细胞外信号调节激酶激酶（MEK）抑制剂在克服耐药性方面的潜在作用。最后，综述了三阴性乳腺癌联合免疫检查点抑制剂的新兴抗体药物偶联物治疗类别。
化疗药物的类型和顺序在优化免疫检查点抑制剂的反应方面发挥着重要作用。抗体药物偶联物与免疫检查点抑制剂联合使用是一个很有前途的发展领域。
